Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile, with sustained efficacy in treating hypoactive sexual desire disorder in premenopausal women.

[1]  J. Simon,et al.  Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder , 2019, Obstetrics and gynecology.

[2]  L. Derogatis,et al.  Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. , 2019, The journal of sexual medicine.

[3]  S. Stahl,et al.  Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review , 2020, Mayo Clinic proceedings.

[4]  L. Derogatis,et al.  Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial , 2016, Women's health.

[5]  S. Hahn,et al.  Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment. , 2016, Sexual medicine reviews.

[6]  B. Komisaruk,et al.  Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part II. , 2016, The journal of sexual medicine.

[7]  A. Clayton,et al.  The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder , 2015, CNS Drugs.

[8]  M. Sand,et al.  Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial , 2014, Menopause.

[9]  H. Scholte,et al.  Reduced gray matter volume and increased white matter fractional anisotropy in women with hypoactive sexual desire disorder. , 2014, The journal of sexual medicine.

[10]  M. Tancer,et al.  Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. , 2013, Fertility and sterility.

[11]  L. Derogatis,et al.  Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. , 2013, The journal of sexual medicine.

[12]  L. Derogatis,et al.  Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. , 2012, The journal of sexual medicine.

[13]  L. Taylor,et al.  Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. , 2012, The journal of sexual medicine.

[14]  M. Sand,et al.  Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. , 2011, The journal of sexual medicine.

[15]  P. Vuilleumier,et al.  Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study. , 2011, The journal of sexual medicine.

[16]  J. Desmond,et al.  Women with hypoactive sexual desire disorder compared to normal females: A functional magnetic resonance imaging study , 2009, Neuroscience.

[17]  C. Johannes,et al.  Sexual Problems and Distress in United States Women: Prevalence and Correlates , 2008, Obstetrics and gynecology.

[18]  F. Giuliano,et al.  Bremelanotide: an overview of preclinical CNS effects on female sexual function. , 2007, The journal of sexual medicine.

[19]  P. Molinoff,et al.  Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Molinoff,et al.  PT‐141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction , 2003, Annals of the New York Academy of Sciences.

[21]  R. Basson.  Biopsychosocial models of women's sexual response: applications to management of ‘desire disorders’ , 2003 .

[22]  R. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston,.  The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function , 2000 .